Gritstone bio Inc. (GRTS) Financial Statements (2025 and earlier)

Company Profile

Business Address 5959 HORTON STREET, SUITE 300
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments46,30379,27483,948114,533145,808171,887
Cash and cash equivalents42,39562,98629,53941,41447,12855,498
Short-term investments3,90816,28854,40973,11998,680116,389
Restricted cash and investments1,2472,2991,2422,4372,0773,977
Prepaid expense6209404061,5368131,158
Deferred costs 440     
Other current assets566778824718728567
Other undisclosed current assets2,6774,1444,4003,1525,3395,289
Total current assets:51,85387,43590,820122,376154,765182,878
Noncurrent Assets
Operating lease, right-of-use asset65,05766,83970,90971,98515,61517,481
Property, plant and equipment14,08817,28118,95220,44320,36521,335
Long-term investments and receivables      4,031
Long-term investments      4,031
Restricted cash and investments5,2905,2905,2905,2905,2905,290
Other undisclosed noncurrent assets9249241,2462,52913,9179,739
Total noncurrent assets:85,35990,33496,397100,24755,18757,876
TOTAL ASSETS:137,212177,769187,217222,623209,952240,754
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,3895,0325,9256,3779,09812,818
Accounts payable7,2483,8194,2654,9255,9758,694
Accrued liabilities2,1411,2131,6601,4523,1234,124
Deferred revenue1,2852,3501,3012,8182,8015,131
Other undisclosed current liabilities15,19619,95716,15712,91612,77316,852
Total current liabilities:25,87027,33923,38322,11124,67234,801
Noncurrent Liabilities
Long-term debt and lease obligation40,33040,14429,86829,72329,57619,349
Long-term debt, excluding current maturities40,33040,14429,86829,72329,57619,349
Liabilities, other than long-term debt57,04858,43659,98461,22214,82615,823
Other liabilities907709554398251150
Operating lease, liability56,14157,72759,43060,82414,57515,673
Total noncurrent liabilities:97,37898,58089,85290,94544,40235,172
Total liabilities:123,248125,919113,235113,05669,07469,973
Equity
Equity, attributable to parent13,96451,85073,982109,567140,878170,781
Common stock222222222222
Additional paid in capital713,889711,386702,755699,979695,961691,910
Accumulated other comprehensive income (loss)(1)3(52)(125)(52)(80)
Accumulated deficit(699,946)(659,561)(628,743)(590,309)(555,053)(521,071)
Total equity:13,96451,85073,982109,567140,878170,781
TOTAL LIABILITIES AND EQUITY:137,212177,769187,217222,623209,952240,754

Income Statement (P&L) ($ in thousands)

6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
Revenues1,74210,3831,5651,9552,4434,262
Gross profit:1,74210,3831,5651,9552,4434,262
Operating expenses(41,543)(40,854)(40,169)(37,683)(37,259)(36,181)
Operating loss:(39,801)(30,471)(38,604)(35,728)(34,816)(31,919)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
 (4)(6)(22)  
Interest and debt expense (1,296)(1,218)(991)(985)(844)(684)
Net loss:(41,097)(31,693)(39,601)(36,735)(35,660)(32,603)
Other undisclosed net income (loss) attributable to parent7128751,1671,4791,6781,313
Net loss available to common stockholders, diluted:(40,385)(30,818)(38,434)(35,256)(33,982)(31,290)

Comprehensive Income ($ in thousands)

6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
Net loss:(41,097)(31,693)(39,601)(36,735)(35,660)(32,603)
Comprehensive loss:(41,097)(31,693)(39,601)(36,735)(35,660)(32,603)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7089301,2401,4061,7061,514
Comprehensive loss, net of tax, attributable to parent:(40,389)(30,763)(38,361)(35,329)(33,954)(31,089)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: